title: The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
abstract: The identification of tumor-associated antigens expressed by colorectal carcinoma remains one of the major goals for designing novel immunological treatments for this tumor. By using a reverse-immunology approach, we show here that the inhibitor of apoptosis protein, survivin, is immunogenic in colorectal cancer patients. In particular, we found that survivin elicited CD8(+) T cell-mediated responses in peripheral blood or in tumor-associated lymphocytes from patients at different disease stage. Colorectal carcinoma cells were recognized by survivin-specific T lymphocytes, and the survivin-specific, class-I HLA-restricted T lymphocytes were fully activated and released interleukin-2 in response to HLA/survivin-peptide complexes expressed by tumor cells. In addition to CD8-mediated responses, survivin specifically stimulated CD4+ T-cell reactivity in peripheral blood lymphocytes from the same patients, thus suggesting that a complete activation of the immune system may occur in response to this antiapoptotic protein. These findings indicate that survivin could be considered a valuable tumor-associated antigen for immune-based clinical approaches in colorectal cancer.
authors.affiliation: Unit of Immunotherapy of Human Tumors, Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian 1, 20133 Milan, Italy. chiara.castelli@istitutotumori.mi.it
authors.forename: Chiara
authors.initials: C
authors.lastname: Casati
authors.forename: Piero
authors.initials: P
authors.lastname: Dalerba
authors.forename: Licia
authors.initials: L
authors.lastname: Rivoltini
authors.forename: Gianfrancesco
authors.initials: G
authors.lastname: Gallino
authors.forename: Paola
authors.initials: P
authors.lastname: Deho
authors.forename: Francesca
authors.initials: F
authors.lastname: Rini
authors.forename: Filiberto
authors.initials: F
authors.lastname: Belli
authors.forename: Delia
authors.initials: D
authors.lastname: Mezzanzanica
authors.forename: Aurora
authors.initials: A
authors.lastname: Costa
authors.forename: Salvatore
authors.initials: S
authors.lastname: Andreola
authors.forename: Ermanno
authors.initials: E
authors.lastname: Leo
authors.forename: Giorgio
authors.initials: G
authors.lastname: Parmiani
authors.forename: Chiara
authors.initials: C
authors.lastname: Castelli
mesh_terms: D000368:Aged; D000595:Amino Acid Sequence; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005260:Female; D015789:HLA-A2 Antigen / Q000276:immunology / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D008875:Middle Aged; D009363:Neoplasm Proteins; D010446:Peptide Fragments / Q000276:immunology / Q000494:pharmacology; D000077022:Survivin; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: C107489:BIRC5 protein, human; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D000077022:Survivin